Pharma companies settle bowel disease drug dispute

Pharmaceutical companies from Canada and Italy have agreed to settle a US$365 million ICC dispute over the development of a drug used in the treatment of inflammatory bowel disease.

Unlock unlimited access to all Global Arbitration Review content